Biocept, Inc. (BIOC)
(Delayed Data from NSDQ)
$0.91 USD
+0.01 (1.10%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Biocept, Inc. [BIOC]
Reports for Purchase
Showing records 41 - 60 ( 65 total )
Company: Biocept, Inc.
Industry: Medical Services
New Test and New Pharma Agreement; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Biocept, Inc.
Industry: Medical Services
New Test and New Pharma Agreement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Biocept, Inc.
Industry: Medical Services
1Q 2016 Financial Results; Reiterate Buy But Adjusting Price Target to $2.50
Provider: H.C. Wainwright & Co., Inc.
Company: Biocept, Inc.
Industry: Medical Services
1Q 2016 Financial Results; Reiterate Buy But Adjusting Price Target
Provider: Rodman & Renshaw, Co.
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
Clinical Advisory Board of Expert Oncologists Formed; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Biocept, Inc.
Industry: Medical Services
Clinical Advisory Board of Expert Oncologists Formed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Biocept, Inc.
Industry: Medical Services
Biopharma Clinical Trial Collaboration; Israeli Distribution; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Biocept, Inc.
Industry: Medical Services
Biopharma Clinical Trial Collaboration; Israeli Distribution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
New NSCLC Treatment Expands Market for Biocept; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
We are initiating coverage with a Buy rating and a 12-month price target of $4 per share
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Biocept, Inc.
Industry: Medical Services
Q2 results mixed, new metrics detailed, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Biocept, Inc.
Industry: Medical Services
Q1 results mixed, underlying trends positive, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Biocept, Inc.
Industry: Medical Services
Q4 commercial tests ahead of model, recent raise puts sufficient capital in place
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Biocept, Inc.
Industry: Medical Services
Q3 results, lung cancer test launched, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B